Key result
Coronary slow flow phenomenon was associated with significantly increased platelet aggregability induced by ristocetin, collagen, and ADP compared to normal coronary flow (p < 0.05).
Why the study?
Is platelet aggregability increased in patients with coronary slow flow phenomenon compared to those with normal coronary flow?
Population
47 patients evaluated for chest pain with angiographically normal coronary arteries, including 24 with…
Design
Case-control
Authors
Loading...
May suggest platelet involvement in CSFP; leaves open whether testing or therapy alters outcomes.
Case-Control (n=47)
Is platelet aggregability increased in patients with coronary slow flow phenomenon compared to those with normal coronary flow?
p-value: p=< 0.05
Patients with coronary slow flow phenomenon exhibit increased platelet aggregability, suggesting a potential pathophysiological role of platelet dysfunction in this condition.
Gökçe et al. (2005) conducted a case-control in Coronary slow flow phenomenon (n=47). Coronary slow flow phenomenon vs. Normal coronary flow was evaluated on Platelet aggregability induced by ristocetin, collagen, and ADP (p=< 0.05). Coronary slow flow phenomenon was associated with significantly increased platelet aggregability induced by ristocetin, collagen, and ADP compared to normal coronary flow (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: